COVID-19: Keep up to date with the latest pharmaceutical and healthcare news as the pandemic evolves

The Pharma Fast 50

PharmaTimes presents Alantra’s annual ranking of the fastest growing private pharma companies in the UK
Powerful progress

Veeva’s predictions for the life sciences industry in 2021
Cash controllers

Oli Hudson and Steve How, of Wilmington Healthcare, explore how NHS England’s new system-level funding works and the impact on prescribing for high cost drugs

News

View all

MHRA approves label extension for Vertex’s Kaftrio combo

Extension of indication expands access to drug for additional cystic fibrosis patients in Great Britain

11th May 2021

Phico Therapeutics raises £7m to advance next-gen antibiotic candidate

Funds will support continued development of company's SASPject platform and progression of lead product PT3.9

11th May 2021

US approves Pfizer COVID-19 vaccine for children aged 12 to 15

First COVID-19 jab to be approved for emergency use in the US for this younger age group

11th May 2021

SMC endorses Alexion’s Ultomiris

Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions

11th May 2021

Positive CHMP opinion for self-administered Crysvita

Crysvita is used for the treatment of the rare metabolic bone disease X-linked hypophosphataemia (XLH)

10th May 2021

Web Exclusives

View all

Smart People: Jeff Elton

Jeff Elton, chief executive of ConcertAI, talks to PharmaTimes about the pandemic's impact on oncology trials in the US

Predicting risk

How pharma can use natural language processing for drug safety predictions

Getting the brand story right

Optimising value propositions for payers – some simple rules

Consumer vision: the decade ahead

A theme of the decade that health chief marketing officer's can’t afford to ignore

Magazine

View more from the latest edition

Class of 2021

Drug development triumphs amidst a challenging 2020

MAGAZINE EXCLUSIVE

Price versus prevalence

Orphan drugs in England – is disease rarity valued by decision makers?

MAGAZINE EXCLUSIVE

Thumbnail image for Care in the community

Mads Mikkelsen reminds us of the crucial role pharmacies play in the healthcare system and considers the adaptations they will have to make to thrive post-pandemic in a world that demands more from its high street

SMART PEOPLE: Dr Steve Cutler

PharmaTimes talks to Dr Steve Cutler, chief executive officer at ICON plc, about the impact of the COVID pandemic and challenges of running large-scale vaccine trials

SMART PEOPLE: Jackie Williams

Jackie Williams, general manager, Astellas UK & Ireland, on her achievements, COVID-19, the challenges and opportunities for pharma and the need for progress in how we value innovation

Stretch, grow and learn

Learning agility and curiosity: the way we future-proof our industry

15 years of biosimilar access in Europe

Learning from the past to shape the future

Approach with intent

Purpose proves itself: permission for pharma to explore better ways to partner with customers and regulators

Thought Leadership

View all

Why virtual engagement will be key to pharma strategy in 2021 and beyond

Life science companies were challenged by the sudden shift in ways of working as the COVID-19 pandemic began. But in moving critical work and even some large-scale events to virtual platforms, pharmaceutical teams learned valuable lessons and embraced new technologies that will become part of their long-term strategy.

What does the future of cancer care in the UK look like?

The COVID-19 pandemic has brought into question how we approach care across multiple disease areas in the future. But what does this mean in cancer? Hear from Bristol Myers Squibb’s (BMS) Executive Medical Director, Hubert Bland, who believes that in order to advance in cancer care, we must learn from the COVID-19 response and adopt a collaborative approach across the healthcare industry.

Digitally-savvy and relationship-smart

To deliver high standards of support to healthcare professionals we have to be both digitally-savvy and relationship-smart

Parkinson’s disease: new real-world data available on safinamide

Dr Jason Raw outlines key findings from the SYNPASES trial, which explored the tolerability of safinamide used as an adjunct therapy in patients with Parkinson's disease